Eli Lilly and Company (LLY)
Eli Lilly and Company R&D Expense: 1.152B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LLY R&D Expense Rankings
| Overall | 0th percentile | 1746 of 1763 |
| Sector | 1st percentile | 406 of 413 in Healthcare |
| Industry | 28th percentile | 18 of 25 in Drug Manufacturers - Major |
LLY R&D Expense Range, Past 5 Years
| Minimum | 844.50M | Sep 2007 |
| Maximum | 1.438B | Dec 2010 |
| Average | 1.094B |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these LLY related companies
LLY News
Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
May 24, 9:02AM Street Insider
May 24, 9:02AM Street Insider
Pharma has been a place to hide in pullback, but there are many fewer names that look healthy. $PFE still holding, $LLY looks ready to drop
about 11 days ago by harmongreg
about 11 days ago by harmongreg
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 15 days ago by laughing_stock
about 15 days ago by laughing_stock
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 15 days ago by abubnic
about 15 days ago by abubnic
Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
May 14, 9:00AM PR Newswire
May 14, 9:00AM PR Newswire
Ex-Dividend Stocks: DuPont, AK Steel http://stks.co/3lBo My story via @TheStreet $DD $AKS $LLY $BTU $EXC $HLF #ExDividend #Dividend
about 20 days ago by azendrian
about 20 days ago by azendrian
$LLY MACDBullish Trend Chart pat UpTrend RSI Bullish Up/Down vol pat under Accum 50/200d MA Bullish Support 39.47 above Resis 40.12 Bullis
about 24 days ago by MACDaddy
about 24 days ago by MACDaddy
Stock Trading Ideas for the Week of 5/7/12 http://stks.co/3gjx via @alphatrends $LLY $ARBA $MM
about 24 days ago by StockTwits
about 24 days ago by StockTwits
FDA Approves Amyvid for Alzheimer’s Diagnosis. $LLY http://stks.co/3ZNn
about 31 days ago by abubnic
about 31 days ago by abubnic
News related to $LLY, currently +0.3% since open: 'ImmunoGen fiscal 3Q loss widens as expenses rise' http://stks.co/3YQK
about 33 days ago by TradeBot
about 33 days ago by TradeBot
$LLY another strong healthcare name trying to breakout. Low volatility also vs SPX. $XLV http://stks.co/3Xg3
about 34 days ago by tradewithpete
about 34 days ago by tradewithpete
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LLY | 41.00 | -0.30 | -0.73% | 47.92B |
| LLTC | 29.09 | -0.33 | -1.12% | 6.737B |
| LLNW | 2.74 | -0.03 | -1.08% | 288.69M |
| LLL | 67.63 | -0.27 | -0.40% | 6.715B |
| LLEN | 1.59 | -0.10 | -5.92% | 55.60M |
| LL | 29.40 | -0.58 | -1.93% | 840.04M |
| LKQX | 36.28 | +0.75 | +2.11% | 5.345B |
| KERX | 1.65 | -0.05 | -2.94% | 120.73M |
| KEQU | 8.25 | -0.02 | -0.24% | 21.28M |
| KEP | 9.40 | -0.12 | -1.26% | 12.22B |
